Finch (Drug Discovery) Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
18
- Stock Symbol
-
FNCH
- Investments
-
1
- Share Price
-
$0.28
- (As of Friday Closing)
Finch (Drug Discovery) General Information
Description
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
Contact Information
- 200 Inner Belt Road
- Suite 400
- Somerville, MA 02143
- United States
Finch (Drug Discovery) Timeline
Finch (Drug Discovery) Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.28 | $0.28 | $0.25 - $3.00 | $13.3M | 48.1M | 276K | -$3.22 |
Finch (Drug Discovery) Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 222 | (9,952) | 324,163 | |
| Revenue | 614 | 861 | 18,532 | 7,719 |
| EBITDA | (152,600) | (109,391) | (55,881) | (38,657) |
| Net Income | (154,018) | (114,646) | (58,160) | (39,341) |
| Total Assets | 79,040 | 162,939 | 225,369 | 165,338 |
| Total Debt | 36,135 | 52,339 | 6,015 | 1,808 |
Finch (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Finch (Drug Discovery) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Finch (Drug Discovery) Comparisons
Industry
Financing
Details
000000
000000
Finch (Drug Discovery) Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 00000000 | Venture Capital-Backed | Paris, France | 00 | 00000 | 00000 00000 | |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Woburn, MA | 00 | 00000 | 00000000000 | 00000 |
Finch (Drug Discovery) Patents
Finch (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020366529-A1 | Compositions and methods for delivering a bacterial metabolite to a subject | Pending | 18-Oct-2019 | 000000000 | |
| CA-3158132-A1 | Compositions and methods for delivering a bacterial metabolite to a subject | Pending | 18-Oct-2019 | 000000000 | |
| EP-4045630-A1 | Compositions and methods for delivering a bacterial metabolite to a subject | Pending | 18-Oct-2019 | 000000000 | |
| AU-2020346061-A1 | Compositions and methods for treating autism spectrum disorder | Pending | 13-Sep-2019 | 0000000000 | |
| CA-3154308-A1 | Compositions and methods for treating autism spectrum disorder | Pending | 13-Sep-2019 | A61K35/747 |
Finch (Drug Discovery) Executive Team (21)
Finch (Drug Discovery) Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrew Mulderry | Finch (Drug Discovery) | Board Member | 000 0000 |
| Chris Lange | Shumway Capital | Board Member | 000 0000 |
| Chris Shumway | Self | Board Member | 000 0000 |
| Domenic Ferrante | Finch (Drug Discovery) | Board Member | 000 0000 |
| Jeffrey Smisek JD | Self | Board Member | 000 0000 |
Finch (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Finch (Drug Discovery) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Finch (Drug Discovery) Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 23-Oct-2017 | 0000000000 | Biotechnology | 0000 0000 |
Finch (Drug Discovery) ESG
Risk Overview
Risk Rating
Updated January, 10, 2023
21.5 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile
Healthcare
Industry
00 of 636
Rank
Percentile
Medical Services
Subindustry
00 of 115
Rank
Percentile
